FES - FES proto-oncogene, tyrosine kinase Gene

中文名称：FES 原癌基因，酪氨酸激酶

种属: Homo sapiens

同用名: FPS

基因 ID: 2242 | 基因类型: protein coding

关于 FES

Cytogenetic location: 15q26.1 Genomic coordinates (GRCh38): 15:90,884,504-90,895,776 (from NCBI)

This gene has 17 transcripts (splice variants), 193 orthologues, 32 paralogues and is associated with 56 phenotypes. Broad expression in spleen (RPKM 39.1), bone marrow (RPKM 25.6) and 23 other tissues.

功能概要

该基因编码具有转化能力的猫肉瘤逆转录病毒蛋白的人类细胞对应物。该基因产物具有酪氨酸特异性蛋白激酶活性，并且该活性是维持细胞转化所必需的。其染色体位置已将其与在急性早幼粒细胞白血病患者中发现的特定易位事件联系起来，但它也参与正常的造血以及生长因子和细胞因子受体信号传导。可变剪接导致编码不同异构体的多个变体。[RefSeq 提供，2009 年 1 月]

This gene encodes the human cellular counterpart of a feline sarcoma retrovirus protein with transforming capabilities. The gene product has tyrosine-specific protein kinase activity and that activity is required for maintenance of cellular transformation. Its chromosomal location has linked it to a specific translocation event identified in patients with acute promyelocytic leukemia but it is also involved in normal hematopoiesis as well as growth factor and cytokine receptor signaling. Alternative splicing results in multiple variants encoding different isoforms.[provided by RefSeq, Jan 2009]

FES 基因产物(4)

mRNA	Protein	Name
NM_001143783.1	NP_001137255.1	tyrosine-protein kinase Fes/Fps isoform 2
NM_001143784.1	NP_001137256.1	tyrosine-protein kinase Fes/Fps isoform 3
NM_001143785.2	NP_001137257.1	tyrosine-protein kinase Fes/Fps isoform 4
NM_002005.4	NP_001996.1	tyrosine-protein kinase Fes/Fps isoform 1

FES 蛋白结构

FCH

SH2

Pkinase_Tyr

0
200
400
600
822 a.a.

蛋白主名

其他名称

tyrosine-protein kinase Fes/Fps

Oncogene FES, feline sarcoma virus

重组 FES 蛋白

目录号	产品名	蛋白编号	纯度
HY-P73050	FES Protein, Human (sf9, His-GST)	P07332-1 (M1-R822)	≥95%

关联疾病

疾病名称

别名

Sarcoma

Connective And Soft Tissue Neoplasm	Tumor Of Soft Tissue And Skeleton
Sarcomas	Sarcoma - Category

Myeloid Leukemia

Myeloid Leukaemia	Leukaemia Myelogenous
Leukemia Myelogenous	Myeloid Granulocytic Leukaemia
Myeloid Granulocytic Leukemia	Non-Lymphocytic Leukemia
Leukemia, Myeloid	Granulocytic Leukaemia
Myelogenous Leukaemia	Myeloid Leukaemia, Unspecified, Without Mention Of Remission

Leukemia

Leukemias	Leukaemia, Unspecified, Without Mention Of Remission
Aleukemic Leukaemia	Chronic Leukaemia
Subacute Leukaemia	Leukaemia Disorder
Leukaemia Nos

Acute Promyelocytic Leukemia

Leukemia, Acute Promyelocytic	Acute Myeloblastic Leukemia Type 3
Aml M3	APL
Leukemia, Acute Promyelocytic, Somatic	Aml With T(15
17)(Q22	Q12)
(Pml/Raralpha) And Variants	Apml
Acute Myeloblastic Leukemia 3	Acute Myeloid Leukemia With T(15
17)(Q22	Q12)
(Pml/Raralpha) And Variants	Acute Myeloblastic Leukaemia Type 3
Acute Myeloid Leukaemia M3	Acute Myeloid Leukemia M3
Acute Promyelocytic Leukaemia	M3 Anll
Myeloid Leukemia, Acute, M3	Leukemia Promyelocytic Acute
Leukemia, Promyelocytic, Acute	Leukemia, Acute, Promyelocytic

Ewing Sarcoma Of Bone

Ewing'S Sarcoma Of Bone	Bone Ewing Sarcoma
Bone Ewing'S Sarcoma	Bone Localized Ewing Sarcoma
Bone Localized Ewing'S Sarcoma	Ewing'S Sarcoma/Bone Peripheral Primitive Neuroectodermal Tumor
Localized Skeletal Ewing'S Sarcoma	Localized Bone Ewing Sarcoma

Myopathy, Centronuclear, 2

Myopathy, Centronuclear, Autosomal Recessive	Autosomal Recessive Centronuclear Myopathy
CNM2	Centronuclear Myopathy 2
Ar-Cnm	Myotubular Myopathy, Autosomal Recessive
Autosomal Recessive Myotubular Myopathy	Centronuclear Myopathy Autosomal Recessive
Myopathy, Centronuclear, Type 2

Melanoma

Malignant Melanoma	Cutaneous Melanoma
Naevocarcinoma	Malignant Melanomas

Leukemia, Chronic Myeloid

Chronic Myeloid Leukemia	Chronic Myelogenous Leukemia
CML	Chronic Granulocytic Leukemia
Leukemia, Philadelphia Chromosome-Positive, Resistant To Imatinib	Chronic Myeloid Leukaemia
Chronic Granulocytic Leukaemia	Chronic Myelogenous Leukaemia
Myeloid Leukemia, Chronic	Leukemia, Chronic Myelogenous
Leukemia, Chronic Myeloid, Philadelphia Chromosome Positive, Somatic	Cml - Chronic Myelogenous Leukemia
Cgl	Chronic Myelocytic Leukemia
Leukemia, Chronic Myeloid, Atypical	ACML
Atypical Chronic Myeloid Leukemia Bcr-Abl1 Negative	Myeloid Leukemia Chronic
Leukemia, Myeloid, Chronic	Leukemia, Myeloid, Chronic, Atypical, Bcr-Abl Negative
Cml- [Chronic Myeloid Leukaemia]	Cgl - [Chronic Granulocytic Leukaemia]
Chronic Myelocytic Leukaemia

Prostate Cancer

Prostate Carcinoma	Prostate Cancer, Familial
Prostate Neoplasm	Prostate Cancer, Somatic
Prostate Cancer, Susceptibility To	Prostatic Cancer
Prostatic Neoplasms	Hereditary Prostate Cancer
Prostatic Neoplasm	Cancer Of Prostate
Carcinoma Of Prostate	Familial Prostate Cancer
Familial Prostate Carcinoma	Malignant Tumor Of Prostate
Malignant Neoplasm Of Prostate	Prostate Cancer, Familial, Susceptibility To
Malignant Tumor Of The Prostate	Ngp - New Growth Of Prostate
Tumor Of The Prostate	Prostate Cancer, Hereditary
Cancer Of The Prostate	Malignant Neoplasm Of The Prostate
Prostatic Carcinoma	PC
Prca	Cancer, Prostate
Malignant Prostatic Tumour	Malignant Tumour Of Prostate
Primary Prostate Cancer	Primary Malignant Neoplasm Of Prostate
Prostate Gland Cancer

疾病名称	别名
Waldenstroem'S Macroglobulinemia	Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma

相关产品

Approval

生物活性分子 (5)

目录号	产品名	作用方式	纯度	是否罕见病
HY-B0988	Deferoxamine mesylate		99.86%	是
HY-B1625	Deferoxamine		≥98.0%	是
HY-107928	Iron dextran		/	否
HY-108017	Ferric maltol		99.93%	是
HY-16564	Deferasirox (Fe3+ chelate)	Inhibitor	≥98.0%	否

Clinical Phase

生物活性分子 (9)

目录号	产品名	作用方式	纯度	Phase
HY-12040	Elesclomol		99.80%	Phase 3
HY-17609	Difelikefalin	Agonist	99.50%	Phase 3
HY-114758	Pyridoxal isonicotinoyl hydrazone		98.28%	Phase 3
HY-P1714	Apraglutide		99.37%	Phase 3
HY-105239A	Selepressin acetate	Agonist	98.77%	Phase 3
HY-P1714A	Apraglutide TFA		98.01%	Phase 3
HY-105239	Selepressin	Agonist	/	Phase 3
HY-122844	Ifebemtinib	Inhibitor	99.86%	Phase 2
HY-P3516	Barusiban	Antagonist	/	Phase 2

Pre-clinical Phase

生物活性分子 (34)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-D1533	RhoNox-1		98.54%	否
HY-W004544	o-Phenanthroline	Inhibitor	99.88%	否
HY-137805	Ferrozine		99.96%	否
HY-126823	Phen Green SK diacetate (5/6-mixture)		95.33%	否
HY-N0928	Mimosine	Inducer	99.92%	否
HY-W075707	FeTCPP		≥95.0%	否
HY-Y1841	o-Phenanthroline monohydrate	Inhibitor	99.38%	否
HY-N10473	Pulcherriminic acid	Inhibitor	≥98.0%	否
HY-D0945	Xylene Cyanol FF		97.46%	否
HY-156776	HAPSBC		≥95.0%	否
HY-P3267A	Apo-Transferrin	Activator	≥95.0%	否
HY-145157	Ferric nitrilotriacetate		≥98.0%	否
HY-N0046	Notoginsenoside Fe		99.98%	否
HY-136300	PHD-1-IN-1	Inhibitor	99.73%	否
HY-160414	TRX-COBI	Inhibitor	/	否
HY-107928A	Iron–Dextran(Fe 25-35% w/w)		/	否
HY-107928B	Iron–Dextran(Fe 35-40% w/w)		/	否
HY-115832	Ap44mSe		/	否
HY-143249	MtMetAP1-IN-1	Inhibitor	/	否
HY-145286	IMPDH2-IN-2		/	否
HY-149418	BChE/HDAC6-IN-2	Inhibitor	/	否
HY-155158	Anticancer agent 147	Inducer	/	否
HY-157917	Nitro-PAPS disodium dihydrate		/	否
HY-B1159S	Nitroxoline-D4		/	否
HY-D2204	SHP1-IN-1	Inhibitor	/	否
HY-E70311	TLL-10X		/	否
HY-RS04867	FES Human Pre-designed siRNA Set A		/	否
HY-W004544S	o-Phenanthroline-d8	Inhibitor	/	否
HY-W011816	1,2-Hexadecanediol		99.73%	否
HY-W112939	Fe(III)(TDCPP) chloride		/	否
HY-W686216	VK-28		/	否
HY-148340	24RBPyBC		/	否
HY-W112021	2,5-DMBQ		/	否
HY-100332	CP 375		/	否

直系同源

种属	基因名	来源	基因 ID
Mus musculus	FES	MGD	MGI:95514
Bos taurus	FES	VGNC	VGNC:28954
Macaca mulatta	FES	VGNC	VGNC:72637
Rattus norvegicus	FES	RGD	RGD:1564385
Felis catus	FES	VGNC	VGNC:62232
Canis familiaris	FES	VGNC	VGNC:40825
Others	FES	NCBI

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。沪(浦)应急管危经许[2021]201709(QFYS)	站点地图隐私声明
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.	沪ICP备15051369号-4

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。沪(浦)应急管危经许[2021]201709(QFYS)

站点地图隐私声明